American Diversified Holdings Corporation (ADHC) to Acquire GlucoGuard, a AI-Based Medical Device for Managing Nocturnal Hypoglycemia in Diabetic Patients
American Diversified Holdings (ADHC) has announced the acquisition of GlucoGuard, an AI-driven medical device technology from IMD Solutions. GlucoGuard is designed to manage nocturnal hypoglycemia in diabetic patients through non-invasive, continuous glucose monitoring and delivery. The acquisition's terms are undisclosed, with financing expected to be non-dilutive.
GlucoGuard's founder, Zachary Smith, will join ADHC's advisory board alongside Bill Colone. The technology is being developed in partnership with a leading U.S. research university, a biomedical and defense engineering firm, and a top publicly traded company in the Continuous Glucose Monitoring sector.
The GlucoGuard system combines advanced engineering, AI, and mobile app-based monitoring to create an innovative solution for managing nocturnal hypoglycemia, addressing a critical challenge in diabetes care.
American Diversified Holdings (ADHC) ha annunciato l'acquisizione di GlucoGuard, una tecnologia medico-device basata sull'IA di IMD Solutions. GlucoGuard è progettato per gestire l'ipoglicemia notturna nei pazienti diabetici attraverso il monitoraggio e la somministrazione continua della glicemia in modo non invasivo. I termini dell'acquisizione non sono stati resi noti, con finanziamenti previsti per essere non diluitivi.
Il fondatore di GlucoGuard, Zachary Smith, entrerà a far parte del consiglio consultivo di ADHC insieme a Bill Colone. La tecnologia è in fase di sviluppo in collaborazione con un'importante università di ricerca statunitense, un'azienda di ingegneria biomedica e di difesa, e una delle principali società quotate nel settore del monitoraggio continuo della glicemia.
Il sistema GlucoGuard combina ingegneria avanzata, intelligenza artificiale e monitoraggio basato su app mobile per creare una soluzione innovativa per la gestione dell'ipoglicemia notturna, affrontando una sfida critica nell'assistenza diabetica.
American Diversified Holdings (ADHC) ha anunciado la adquisición de GlucoGuard, una tecnología de dispositivo médico impulsada por IA de IMD Solutions. GlucoGuard está diseñado para gestionar la hipoglucemia nocturna en pacientes diabéticos a través de un monitoreo y suministro continuo de glucosa no invasivo. Los términos de la adquisición no se han divulgado, y se espera que el financiamiento no sea dilutivo.
El fundador de GlucoGuard, Zachary Smith, se unirá al consejo asesor de ADHC junto a Bill Colone. La tecnología se está desarrollando en asociación con una universidad de investigación líder en EE. UU., una empresa de ingeniería biomédica y de defensa, y una de las principales compañías que cotizan en bolsa en el sector de Monitoreo Continuo de Glucosa.
El sistema GlucoGuard combina ingeniería avanzada, IA y monitoreo basado en aplicaciones móviles para crear una solución innovadora para la gestión de la hipoglucemia nocturna, abordando un desafío crítico en el cuidado de la diabetes.
American Diversified Holdings (ADHC)는 IMD Solutions의 AI 기반 의료 기기 기술인 GlucoGuard를 인수했다고 발표했습니다. GlucoGuard는 비침습적이고 지속적인 혈당 모니터링과 전달을 통해 당뇨병 환자의 야간 저혈당증을 관리하도록 설계되었습니다. 인수 조건은 공개되지 않았으며, 자금 조달이 희석되지 않을 것으로 예상됩니다.
GlucoGuard의 창립자 Zachary Smith는 Bill Colone와 함께 ADHC의 자문위원회에 합류할 것입니다. 이 기술은 미국의 저명한 연구 대학, 생의학 및 방위 공학회사, 그리고 지속적인 혈당 모니터링 부문의 상장 기업과 협력하여 개발되고 있습니다.
GlucoGuard 시스템은 첨단 엔지니어링, AI 및 모바일 앱 기반 모니터링을 결합하여 야간 저혈당증 관리를 위한 혁신적인 솔루션을 제공합니다. 이는 당뇨 관리에서 중요한 도전에 대응합니다.
American Diversified Holdings (ADHC) a annoncé l'acquisition de GlucoGuard, une technologie de dispositif médical basée sur l'IA provenant d'IMD Solutions. GlucoGuard est conçu pour gérer l'hypoglycémie nocturne chez les patients diabétiques grâce à une surveillance et une délivrance continue de la glucose non invasive. Les conditions de l'acquisition ne sont pas divulguées, avec un financement qui devrait ne pas être dilutif.
Le fondateur de GlucoGuard, Zachary Smith, rejoindra le conseil consultatif d'ADHC aux côtés de Bill Colone. La technologie est développée en partenariat avec une université de recherche américaine de premier plan, une entreprise d'ingénierie biomédicale et de défense, ainsi qu'une grande société cotée en bourse dans le secteur de la surveillance continue de la glucose.
Le système GlucoGuard combine l'ingénierie avancée, l'IA et la surveillance basée sur des applications mobiles pour créer une solution innovante pour la gestion de l'hypoglycémie nocturne, abordant un défi critique dans le soin du diabète.
American Diversified Holdings (ADHC) hat die Übernahme von GlucoGuard angekündigt, einer KI-gestützten Medizintechnologie von IMD Solutions. GlucoGuard wurde entwickelt, um nächtliche Hypoglykämie bei Diabetikern durch nicht-invasive, kontinuierliche Blutzuckerüberwachung und -abgabe zu steuern. Die Bedingungen der Übernahme sind nicht veröffentlicht, wobei eine nicht verwässernde Finanzierung erwartet wird.
Der Gründer von GlucoGuard, Zachary Smith, wird gemeinsam mit Bill Colone in den Beratungsausschuss von ADHC eintreten. Die Technologie wird in Zusammenarbeit mit einer führenden US-Forschunguniversität, einem biomedizinischen und Verteidigungstechnologieunternehmen sowie einem der größten an der Börse notierten Unternehmen im Bereich der kontinuierlichen Blutzuckerüberwachung entwickelt.
Das GlucoGuard-System kombiniert fortschrittliche Technik, KI und mobil-App-basiertes Monitoring, um eine innovative Lösung für die Verwaltung der nächtlichen Hypoglykämie zu schaffen und damit eine kritische Herausforderung in der Diabetesversorgung anzugehen.
- Acquisition of innovative AI-driven medical device technology for managing nocturnal hypoglycemia
- Non-dilutive financing expected for the acquisition
- Addition of GlucoGuard's founder Zachary Smith to ADHC's advisory board
- Partnerships with leading institutions for GlucoGuard's development
- Potential to address a significant unmet need in diabetes care
- None.
GlucoGuard Founder Zachary Smith to Join ADHC as Scientific Advisor
Del Mar, California--(Newsfile Corp. - September 9, 2024) - American Diversified Holdings Corporation (OTC Pink: ADHC) is pleased to announce the acquisition of GlucoGuard, a revolutionary AI-driven medical device technology from IMD Solutions, Phoenix, AZ. GlucoGuard is designed to address the critical challenge of managing nocturnal Hypoglycemia for diabetic patients, offering a breakthrough in non-invasive, continuous glucose monitoring and delivery.
In addition to the acquisition, GlucoGuard's founder, Zachary Smith, BS/MS Biomedical Engineering (Arizona State University), will join ADHC's advisory board. Smith will work alongside Bill Colone, a renowned expert in biomedical solutions, to advance GlucoGuard's development and integration into ADHC's expanding healthcare technology portfolio.
The terms of the acquisition remain undisclosed, but financing is expected to be non-dilutive.
Transforming Diabetes Management
Zachary Smith commented, "ADHC provides the ideal platform for the commercialization of GlucoGuard. Both Bill and I are eager to bring this life-saving technology to market, helping millions of diabetic patients-both adults and children-better manage their glucose levels with greater safety and ease."
Bill Colone added, "Hypoglycemia, particularly during sleep, is a persistent and dangerous issue for diabetic patients, often leading to serious consequences like the dreaded 'Death in Bed' syndrome. GlucoGuard's technology offers a game-changing solution to this pressing problem."
Key Development Partnerships
The GlucoGuard system is being developed in collaboration with three key partners:
- A leading U.S. research university.
- A highly respected biomedical and defense engineering firm.
- A top publicly traded company in the Continuous Glucose Monitoring (CGM) sector.
Further details on these collaborations will be disclosed soon.
Cutting-Edge Technology for Unmet Medical Needs
GlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal Hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effective glucose management without disturbing the patient's rest.
"The GlucoGuard invention is a significant leap forward in addressing one of the most dangerous complications of diabetes," said ADHC management. "We are thrilled to welcome Zachary Smith and his innovative team to ADHC, and we're committed to fast-tracking the development and commercialization of this much-needed technology."
About Artificial Intelligence and Health Care
A recent report from the Mayo Clinic identified three potential benefits of AI in healthcare:
- Improving outcomes for both patients and clinical teams.
- Lowering healthcare costs.
- Benefitting population health.
From preventive screenings to diagnosis and treatment, AI is being used throughout the continuum of care today. Two examples are Preventive Health Care and Risk Assessment.
Cancer Screenings that use radiology can leverage AI to help produce results faster. A noted example is analyzing kidney images in a laborious 45minute process. AI automated process can reduce this analysis to minutes, saving time, money and giving a more accurate diagnosis.
Pre-diabetes patients with no notable symptoms can be screened using AI to determine which type of diabetes they are at risk for and begin preventative care.
See AI in healthcare: The future of patient care and health management - Mayo Clinic Press
About the Diabetes Market
The diabetes market is poised for substantial growth, with the U.S. market valued at
For more information on the
The Continuous Glucose Monitoring (CGM) sector, valued at
For details on the CGM market, visit: Continuous Glucose Monitoring Market.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/222342_e29a545e94f93a0d_001full.jpg
About IMD Solutions, Inc.
IMD Solutions, Inc. is a Nevada-based medical device company developing GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of low blood sugar during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, IMD Solutions is at the forefront of diabetes management technology.
For more information, visit: www.GlucoGuardSleep.com.
Contact: Phone: 817-525-0057
Email: info@GlucoGuardSleep.com
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/7822/222342_e29a545e94f93a0d_002full.jpg
About AMERICAN DIVERSIFIED HOLDINGS CORPORATION
www.UniversalWellnessAI.com
www.UniversalWellnessShop.com
John Cacchioli, CEO
American Diversified Holdings Corporation
Telephone: (212) 537-5900
Email: JC@American-Diversified.com
Social Media:
TWITTER: @ADHCManagement.
This Twitter page is the only official Twitter page for ADHC.
SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/222342
FAQ
What is GlucoGuard and how does it work?
Who are the key partners in developing GlucoGuard for ADHC?
What is the significance of ADHC's acquisition of GlucoGuard?
How will Zachary Smith contribute to ADHC after the acquisition?
